- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05128721
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase I, Randomized, Open-Labeled Clinical trial. Eligible volunteers will be randomized in a 1:1:1 allocation ratio, into one of the three study arms using the Interactive Web Response Technology (IWRS).
Unscheduled visits can occur at any time during the study period outside the initially planned study visits, all the extra visits will be documented in the subjects' files. Volunteers will be randomized into one of the following arms to receive different doses of the Inactivated
SARS-COV-2 Vaccine "NRC-VACC-101" as an intramuscular (IM) Injection or Placebo:
Arm One:
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
Arm Two:
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
Arm Three (Control arm):
Volunteers will receive two IM doses of the placebo, 28 days apart. The first 9 subjects will be initially vaccinated with their first dose, as per their assigned study arm determined by the randomization procedures and will be followed up until day 14 (visit 03). At this point in the study, the Data Safety and Monitoring Board (DSMB) will review safety data before proceeding with vaccinating the rest of the recruited subjects
Studietype
Registrering (Forventet)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Osama Azmy, MD
- Telefonnummer: +201223103084
- E-post: osamaazmy@yahoo.com
Studer Kontakt Backup
- Navn: Clinical Trial Unit Clinical Trial Unit National Research Centre, MD
- Telefonnummer: +20237623009
- E-post: ctu.mrce@nrc.sci.eg
Studiesteder
-
-
Giza
-
Cairo, Giza, Egypt, 12622
- Rekruttering
- Medical Research Centre of Excellence National Research Centre
-
Ta kontakt med:
- Osama Azmy, MD
- Telefonnummer: +201223103084
- E-post: osamaazmy@yahoo.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults with age 18 to 50 years.
- Willingness.
- For married females of childbearing age: Willingness to practice continuous effective contraception for one year from the start of the study.
- Agreement to refrain from blood donation during the study.
- Body temperature is within the normal range (36.5 - 37.5°C).
- General good health as established by medical history, physical and laboratory examinations.
Exclusion Criteria:
- Pregnancy or lactation.
- Inability to provide informed consent.
- Recent receipt of any vaccination within 30 days prior to baseline.
- Planning to receive any vaccination during the course of the study.
- Prior receipt of Adenovirus vaccine, or any other Coronavirus vaccine.
- Recent receipt of any immunoglobulin within 90 days prior to baseline.
- Recent receipt of any blood product within 90 days prior to baseline.
Volunteers who are immunosuppressed or receiving immunosuppressive medications, including:
HIV infection, asplenia, recurrent severe infections, and the use of immunosuppressive medications within the past 6 months, except for topical steroids or short-term oral steroids (course lasting < 14 days).
- Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
- Having any autoimmune disease.
- History of allergic reactions for any of the vaccine components.
- History of angioedema.
- History of anaphylaxis.
- History of cancer.
- History of serious psychiatric conditions that are likely to affect participation in the study.
- Having bleeding disorders.
- Having chronic respiratory diseases.
- Having chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorders, and neurological illness.
- Volunteers with BMI ≥ 40 Kg/m2 or ≤ 18 Kg/m2.
- Current alcohol abuse.
- Drug abuse within 5 years prior to baseline.
- History of laboratory-confirmed COVID-19 or seropositivity for SARS-CoV-2 or positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS CoV-2 or abnormal chest CT-Scan (COVID-19 image) or positive pharyngeal/sputum swabs for SARS-CoV-2.
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
- High-risk population (volunteers who work in front-line health facilities or were in close contact with confirmed COVID-19 cases).
- Living in the same household as anyone at high risk of severe COVID-19.
- Any condition, according to the judgment of the investigator, that would interfere with the subject's ability to comply with all study requirements or that would place the subject at unacceptable risk by his/her participation in the study or impair the interpretation of the study data.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: NRC-VACC-101 vaccine 3 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Andre navn:
|
Aktiv komparator: NRC-VACC-101 vaccine 6 microgram
Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Andre navn:
|
Placebo komparator: Control arm
Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
|
Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection.
NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials.
Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The safety of NRC-VACC-101 Vaccine
Tidsramme: Follow up for any solicited adverse event(AE) reported within 7 days
|
To evaluate the safety of the proposed regimens of NRC-VACC-101
|
Follow up for any solicited adverse event(AE) reported within 7 days
|
The tolerability of NRC-VACC-101 Vaccine
Tidsramme: Follow up for any AE within 28 days of each dose
|
To evaluate the tolerability of the proposed regimens of NRC-VACC-101 Vaccine in the healthy population
|
Follow up for any AE within 28 days of each dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The seroconversion rate of neutralizing antibodies
Tidsramme: The evaluation of the antibody will be measured up to one month of each dose
|
To evaluate the seroconversion rate of neutralizing antibodies resulting from the NRC-VACC-101 Vaccine
|
The evaluation of the antibody will be measured up to one month of each dose
|
To recommend the dose level of NRC-VACC-101 Vaccine for the phase II trial.
Tidsramme: The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
The evaluation of the Microneutralization Assay curve will give an overview of the dose possible suggested dose of NRC-VACC-101 Vaccine for the phase II trial
|
The evaluation of the Microneutralization Assay will be assessed up to one month of each dose
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Osama Azmy, MD, Medical Research and Clinical Studies Institute National Research Centre, Dokki, Giza, Egypt.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NO-B041
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftveisinfeksjon | COVID-19 stresssyndrom | Covid-19-vaksinebivirkning | COVID-19-assosiert tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-assosiert hjerneslagKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbeidspartnereFullførtPostakutte følgetilstander av COVID-19 | Tilstand etter covid-19 | Langvarig COVID | Kronisk COVID-19 syndromItalia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutteringCovid-19-pandemi | Covid-19-vaksiner | COVID-19 virussykdomIndonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkHar ikke rekruttert ennåPost-COVID-19 syndrom | Lang COVID | Lang Covid19 | Tilstand etter covid-19 | Post-COVID syndrom | Tilstand etter COVID-19, uspesifisert | Tilstand etter COVIDNederland
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyFullførtPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
Indonesia UniversityRekrutteringPost-COVID-19 syndrom | Lang COVID | Tilstand etter covid-19 | Post-COVID syndrom | Lang COVID-19Indonesia
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutteringCOVID-19 lungebetennelse | COVID-19 luftveisinfeksjon | Covid-19-pandemi | COVID-19 akutt respiratorisk distress-syndrom | COVID-19-assosiert lungebetennelse | COVID 19 assosiert koagulopati | COVID-19 (Coronavirus Disease 2019) | COVID-19-assosiert tromboembolismeHellas
-
Endourage, LLCRekrutteringLang COVID | Lang Covid19 | Post-akutt COVID-19 | Langdistanse COVID | Langdistanse COVID-19 | Postakutt covid-19 syndromForente stater
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital og andre samarbeidspartnereRekrutteringKohortoppfølging av epidemi og nevroimaging for pasienter under den første bølgen av COVID-19 i KinaCovid-19 | Post-COVID-19 syndrom | Post-akutt COVID-19 | Akutt COVID-19Kina
Kliniske studier på Covi Vax
-
Sorrento Therapeutics, Inc.Tilbaketrukket
-
Sorrento Therapeutics, Inc.Tilbaketrukket
-
Sorrento Therapeutics, Inc.Tilbaketrukket
-
Chonnam National University HospitalUkjentMultippelt myelomKorea, Republikken
-
University of PennsylvaniaPhiladelphia Department of Public HealthFullført
-
Entos Pharmaceuticals Inc.Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical... og andre samarbeidspartnereFullførtSARS-CoV-2Burkina Faso, Canada, Senegal, Sør-Afrika
-
Codagenix, IncFullførtCovid-19Storbritannia
-
Codagenix, IncFullførtCovid-19 | SARS-CoV-2Storbritannia
-
Sorrento Therapeutics, Inc.Rekruttering
-
Sorrento Therapeutics, Inc.TilbaketrukketAkutt lungesviktsyndrom | ARDS